Metabolic Reprogramming and Validation of Hyperpolarized 13C Lactate as a Prostate Cancer Biomarker Using a Human Prostate Tissue Slice Culture Bioreactor

The treatment of prostate cancer has been impeded by the lack of both clinically relevant disease models and metabolic markers that track tumor progression. Hyperpolarized (HP) 13C MR spectroscopy has emerged as a new technology to investigate the metabolic shifts in prostate cancer. In this study, we investigate the glucose reprogramming using HP 13C pyruvate MR in a patient‐derived prostate tissue slice culture (TSC) model.

[1]  R. Gillies,et al.  In vivo magnetic resonance spectroscopy in cancer. , 2005, Annual review of biomedical engineering.

[2]  W. Hahn,et al.  The current state of preclinical prostate cancer animal models , 2008, The Prostate.

[3]  R. Franklin,et al.  hZip2 and hZip3 zinc transporters are down regulated in human prostate adenocarcinomatous glands , 2007, Molecular Cancer.

[4]  R. Vessella,et al.  Serum Glutamate Levels Correlate with Gleason Score and Glutamate Blockade Decreases Proliferation, Migration, and Invasion and Induces Apoptosis in Prostate Cancer Cells , 2012, Clinical Cancer Research.

[5]  Albert P. Chen,et al.  Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. , 2008, Cancer research.

[6]  John Kurhanewicz,et al.  Generation of hyperpolarized substrates by secondary labeling with [1,1-13C] acetic anhydride , 2009, Proceedings of the National Academy of Sciences.

[7]  A W Partin,et al.  Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. , 2001, The Journal of urology.

[8]  R G Shulman,et al.  31P nuclear magnetic resonance studies of bioenergetics and glycolysis in anaerobic Escherichia coli cells. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[9]  M. Weiner,et al.  31P spectroscopy of the human prostate gland in vivo using a transrectal probe , 1991, Magnetic resonance in medicine.

[10]  P. Carroll,et al.  Quantitative analysis of prostate metabolites using 1H HR‐MAS spectroscopy , 2006, Magnetic resonance in medicine.

[11]  D. Peehl.  Are primary cultures realistic models of prostate cancer? , 2004, Journal of cellular biochemistry.

[12]  J. Kurhanewicz,et al.  Generating contrast in hyperpolarized 13C MRI using ligand-receptor interactions. , 2012, The Analyst.

[13]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[14]  Daniel B. Vigneron,et al.  Advances in MR spectroscopy of the prostate. , 2008, Magnetic resonance imaging clinics of North America.

[15]  O. Warburg,et al.  THE METABOLISM OF TUMORS IN THE BODY , 1927, The Journal of general physiology.

[16]  P. Carroll,et al.  Metabolic, pathologic, and genetic analysis of prostate tissues: quantitative evaluation of histopathologic and mRNA integrity after HR‐MAS spectroscopy , 2010, NMR in biomedicine.

[17]  A. Shojaie,et al.  Metabolomic Profiling Reveals a Role for Androgen in Activating Amino Acid Metabolism and Methylation in Prostate Cancer Cells , 2011, PloS one.

[18]  O. Bagasra,et al.  hZIP1 zinc uptake transporter down regulation and zinc depletion in prostate cancer , 2005, Molecular Cancer.

[19]  L. Hutchinson,et al.  High drug attrition rates—where are we going wrong? , 2011, Nature Reviews Clinical Oncology.

[20]  Lillian L. Siu,et al.  Preclinical development of molecular-targeted agents for cancer , 2011, Nature Reviews Clinical Oncology.

[21]  P. Walsh,et al.  Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The Journal of urology.

[22]  R. Deberardinis,et al.  Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? , 2012, Cell.

[23]  J. Kurhanewicz,et al.  Methods for metabolic evaluation of prostate cancer cells using proton and 13C HR‐MAS spectroscopy and [3‐13C] pyruvate as a metabolic substrate , 2009, Magnetic resonance in medicine.

[24]  Saumyadipta Pyne,et al.  Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors , 2010, Proceedings of the National Academy of Sciences.

[25]  N. Kyprianou,et al.  Modeling prostate cancer in mice: limitations and opportunities. , 2012, Journal of andrology.

[26]  A. Thomson,et al.  Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[27]  N. Greenberg,et al.  A Transgenic Mouse Prostate Cancer Model , 1996, Toxicologic pathology.

[28]  John Kurhanewicz,et al.  Hyperpolarized 13C dehydroascorbate as an endogenous redox sensor for in vivo metabolic imaging , 2011, Proceedings of the National Academy of Sciences.

[29]  T. Stamey,et al.  PATTERNS OF PROGRESSION IN PROSTATE CANCER , 1986, The Lancet.

[30]  P. Carroll,et al.  Proton HR‐MAS spectroscopy and quantitative pathologic analysis of MRI/3D‐MRSI‐targeted postsurgical prostate tissues , 2003, Magnetic resonance in medicine.

[31]  C. Logothetis,et al.  A New Therapy Paradigm for Prostate Cancer Founded on Clinical Observations , 2010, Clinical Cancer Research.

[32]  R. Nolley,et al.  Metabolic , Endocrine and Genitourinary Pathobiology Tissue Slice Grafts An in Vivo Model of Human Prostate Androgen Signaling , 2010 .

[33]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[34]  P. Nelson,et al.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. , 2003, Cancer cell.

[35]  D. Peehl.  Primary cell cultures as models of prostate cancer development. , 2005, Endocrine-related cancer.

[36]  S. Majumdar,et al.  Correlation of HR-MAS Spectroscopy Derived Metabolite Concentrations With Collagen and Proteoglycan Levels and Thompson Grade in the Degenerative Disc , 2005, Spine.

[37]  John Kurhanewicz,et al.  Hyperpolarized 13C spectroscopy and an NMR‐compatible bioreactor system for the investigation of real‐time cellular metabolism , 2010, Magnetic resonance in medicine.

[38]  R. Medema,et al.  Human prostate epithelium lacks Wee1A-mediated DNA damage-induced checkpoint enforcement , 2007, Proceedings of the National Academy of Sciences.

[39]  Pernille R. Jensen,et al.  Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate , 2008, Nature.

[40]  J S Petersson,et al.  Molecular imaging using hyperpolarized 13C. , 2003, The British journal of radiology.

[41]  J. Kurhanewicz,et al.  Correlation of phospholipid metabolites with prostate cancer pathologic grade, proliferative status and surgical stage – impact of tissue environment , 2011, NMR in biomedicine.

[42]  S. Bröer,et al.  The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. , 2000, The Biochemical journal.

[43]  John Kurhanewicz,et al.  Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. , 2011, Neoplasia.

[44]  M. Sadar,et al.  Cell lines used in prostate cancer research: a compendium of old and new lines--part 1. , 2005, The Journal of urology.

[45]  Gavin Kelly,et al.  Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival. , 2012, Cancer discovery.

[46]  Hans Garmo,et al.  Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer , 2011 .

[47]  D. Peehl.  Human Prostatic Epithelial Cells , 2002 .

[48]  C. Begley,et al.  Drug development: Raise standards for preclinical cancer research , 2012, Nature.

[49]  J. Kurhanewicz,et al.  Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR‐MAS spectroscopy of biopsy tissues , 2008, Magnetic resonance in medicine.

[50]  B. Conley,et al.  Endoglin regulates cancer-stromal cell interactions in prostate tumors. , 2011, Cancer research.

[51]  T. Ylikomi,et al.  A novel tissue-slice culture model for non-malignant human prostate , 2008, Cell and Tissue Research.

[52]  Guido Kroemer,et al.  Tumor cell metabolism: cancer's Achilles' heel. , 2008, Cancer cell.

[53]  L. Chung,et al.  Stromal-epithelial interaction in prostate cancer progression. , 2006, Clinical genitourinary cancer.

[54]  John T. Wei,et al.  Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  John Kurhanewicz,et al.  Multi-compound polarization by DNP allows simultaneous assessment of multiple enzymatic activities in vivo. , 2010, Journal of magnetic resonance.